Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 13/20 | 0.59 |
| ▸ | AKR1B10 | O60218 | 12/20 | 0.59 |
| ▸ | AKR1A1 | P14550 | 8/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | KRAS | P01116 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1120444 | 0.87 | AKR1B1 (0.53) | AKR1B1AKR1B10AKR1A1KDM4EHSD17B10 | |
| SCHEMBL1120434 | 0.86 | AKR1B1 (0.70) | AKR1B1AKR1B10AKR1A1 | |
| SCHEMBL1120368 | 0.86 | AKR1B1 (0.59) | AKR1B1AKR1B10AKR1A1KDM4EALDH1A1 | |
| SCHEMBL1120467 | 0.85 | AKR1B1 (0.58) | AKR1B1AKR1B10AKR1A1MEN1MAPT | |
| SCHEMBL1120457 | 0.84 | AKR1B1 (0.51) | AKR1B1AKR1B10AKR1A1KDM4EALDH1A1 | |
| SCHEMBL1120374 | 0.84 | AKR1B1 (0.62) | AKR1B1AKR1B10AKR1A1KDM4EALDH1A1 | |
| SCHEMBL1120438 | 0.83 | AKR1B1 (0.61) | AKR1B1AKR1B10AKR1A1MEN1MAPT | |
| SCHEMBL1120354 | 0.82 | AKR1B1 (0.49) | AKR1B1AKR1B10AKR1A1MEN1MAPT | |
| SCHEMBL2846607 | 0.74 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1 | |
| SCHEMBL411220 | 0.73 | KDM4E (0.56) | AKR1B1AKR1B10AKR1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9469641-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-9260429-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20130190323-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130184306-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130131077-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130079352-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-8338447-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2280968-A2 | PYRIDO [3, 4-B]INDOLES AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2011-02-09 | — | — | EP | disclosed |
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2009-10-29 | — | — | US | disclosed |
| WO-2009120717-A2 | PYRIDO [3, 4-B] INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184306-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | AKR1B1 1678/4885AKR1B10 2570/4885AKR1A1 2547/4885 |
| US-20130079352-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | AKR1B1 1678/4885AKR1B10 2570/4885AKR1A1 2547/4885 |
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | AKR1B1 1678/4885AKR1B10 2570/4885AKR1A1 2547/4885 |
| US-20130190323-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | AKR1B1 1678/4885AKR1B10 2570/4885AKR1A1 2547/4885 |
| US-20130131077-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR2C, HTR4 | AKR1B1 1481/4885AKR1B10 2349/4885AKR1A1 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.